



## **MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alzheimer's Disease, in Madrid at the end of October 2024 (CTAD, Clinical Trials Alzheimer's Disease)**

Montpellier, October 8, 2024 at 8:00am CET. – **MEDESIS PHARMA**, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles via the endo-oral mucosal route **Aonys®**, announces that its teams of experts will be present at the **CTAD Congress** to meet the Medical Directors of several Pharmaceutical Laboratories, with the goal of selling a license for the future development of **Nanolithium®**.

### **Recent results from the first phase of the Phase 2A clinical study demonstrate the clinical efficacy of NanoLithium for the treatment of severe symptoms of Alzheimer's disease**

After the analysis of the results by clinical experts, **Nanolithium**, in this proof-of-concept study, achieved its objective by showing a **49% reduction in psycho-behavioral symptoms in patients with Alzheimer's disease compared to a placebo**, without however reaching statistical significance, due to a large variability in the patients' symptoms and a limited sample size of patients.

The change in NPI score is within the range of the expected effect and, according to clinical experts, including Pr. Jacques Touchon (Professor Emeritus at the University of Montpellier, Editor-in-Chief of the Journal of Prevention of Alzheimer's disease (JPAD), Co-Chairman and founding member of the Clinical Trials on Alzheimer's Disease (CTAD) conference, member of the Medesis Pharma Scientific Advisory Board), **the gain in improvement is clinically meaningful, particularly in an indication for the treatment of a disease with no real therapeutic option**. The NPI Score analysed corresponds to the average of the stages of development of 12 symptoms of the disease: delusions, hallucinations, agitation and aggressiveness, depression, anxiety, mood swings, apathy and indifference, disinhibition, irritability, aberrant motor behavior, sleep disorders, appetite disorders. The 68 patients recruited in the 8 university hospitals had very variable scores on these symptoms, preventing the obtaining of a statistically significant result which will require treating a larger number of patients.

**No side effects were observed during treatment, with perfect tolerance of the product.**

**This trial justifies the implementation of a larger study to confirm this result and provides adequate data to establish the sample size of a future trial. Indeed, the result obtained is considered by clinicians as a real prospect of effective treatment for patients suffering from Alzheimer's disease, allowing them to maintain a quality of life at home.**

### **Participation in the CTAD Congress from October 29 to November 1, 2024, in Madrid to meet with pharmaceuticals laboratories**

The results obtained made it possible to inform pharmaceutical laboratories that develop drugs in the field of neurodegenerative diseases, and several of them requested the organization of a meeting with the team of Medesis Pharma, including Professor Jacques Touchon.

Medesis Pharma's goal is to license the NanoLithium product to a pharmaceutical partner who will continue clinical development on a very large number of patients, for registration and then marketing. In view of this objective, Medesis Pharma is in the process of raising the financing needed to pursue its business over the coming months from its shareholders and investors, such as foundations and family offices.

### About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer’s disease, Huntington’s disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, the result of 17 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information:

[www.medesispharma.com](http://www.medesispharma.com)

#### MEDESIS PHARMA

Jean Claude Maurel

Tel: +33 4 67 03 03 96

[contact@medesispharma.com](mailto:contact@medesispharma.com)

#### CALYPTUS

Marie Calleux

Tel : +33 1 53 65 68 66

[medesispharma@calyptus.net](mailto:medesispharma@calyptus.net)